TITLE

Structural Characterisation of Non-Deamidated Acidic Variants of Erwinia chrysanthemi L-asparaginase Using Small-Angle X-ray Scattering and Ion-Mobility Mass Spectrometry

AUTHOR(S)
Gervais, David; King, Darryl; Kanda, Patrick; Foote, Nicholas; Elliott, Lucy; Brown, Phillip; Lee, Natacha; Thalassinos, Konstantinos; Pizzey, Claire; Rambo, Robert; Minshull, Thomas; Dickman, Mark; Smith, Stuart
PUB. DATE
November 2015
SOURCE
Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3636
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Erwinia chrysanthemi L-asparaginase (ErA) is an enzyme commonly used in the treatment regimen for Acute Lymphoblastic Leukaemia (ALL). Biopharmaceutical products such as ErA must be monitored for modifications such as deamidation, typically using ion-exchange chromatography (IEX). Analysis of clinical-grade ErA using native IEX resolves a number of enzymatically-active, acidic variants that were poorly characterised. Methods: ErA IEX variants were isolated and fully characterised using capillary electrophoresis (cIEF), LC-MS and LC-MS/MS of proteolytic digests, and structural techniques including circular dichroism, small-angle X-ray scattering (SAXS) and ion-mobility mass spectrometry (IM-MS). Results: LC-MS, MS/MS and cIEF demonstrated that all ErA isolates consist mainly of enzyme lacking primary-sequence modifications (such as deamidation). Both SAXS and IM-MS revealed a different conformational state in the most prominent acidic IEX peak. However, SAXS data also suggested conformational differences between the main peak and major acidic variant were minor, based on comparisons with crystal structures. Conclusions: IEX data for biopharmaceuticals such as ErA should be thoroughly characterised, as the most common modifications, such as deamidation, may be absent.
ACCESSION #
110202851

 

Related Articles

  • Validation of a 30-year-old process for the manufacture of l-asparaginase from Erwinia chrysanthemi. Gervais, David; Allison, Nigel; Jennings, Alan; Jones, Shane; Marks, Trevor // Bioprocess & Biosystems Engineering;Apr2013, Vol. 36 Issue 4, p453 

    A 30-year-old manufacturing process for the biologic product l-asparaginase from the plant pathogen Erwinia chrysanthemi was rigorously qualified and validated, with a high level of agreement between validation data and the 6-year process database. l-Asparaginase exists in its native state as a...

  • Pegaspargase versus asparaginase in adult ALL: A pharmacoeconomic assessment. Peters, Byron G.; Goeckner, Byron J. // Formulary;Jul95, Vol. 30 Issue 7, p388 

    Discusses the efficacy of pegaspargase as an alternative to asparaginase in the treatment of acute lymphocytic leukemia (ALL). Incidence of hypersensitivity reactions; Benefits of pegaspargase; Limitations of asparaginase; Cost-minimization steps to determine pharmacoeconomic impact of the two...

  • Asparaginase: Fulminant hepatitis: case report.  // Reactions Weekly;Nov2013, Issue 1477, p7 

    The article presents a case report of a woman with Pro-B acute lymphoblastic leukaemia who received asparaginase and developed fulminant hepatitis during treatment.

  • Asparaginase Erwinia chrysanthemi (Erwinaze): A Guide to Its Use in Acute Lymphoblastic Leukemia in the USA. Keating, Gillian // BioDrugs;2013, Vol. 27 Issue 4, p413 

    Asparaginase Erwinia chrysanthemi (Erwinaze) is approved in the USA for use in patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to Escherichia coli-derived asparaginase. The approved regimen of intramuscular Erwinaze was associated with sustained, clinically...

  • AIBioTech LLC Assists EUSA Pharma in Obtaining FDA approval for a Critical Drug Product.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p176 

    The article reports on the approval of EUSA Pharma Biologics' Erwinaze (asparaginase Erwinia chrysanthemi) drug product by the U.S. Food & Drug Administration (FDA). It states that AIBioTech LLC assists EUSA Pharma to obtain FDA approval for the drug product through successful assay validation...

  • Asparaginase/dexamethasone/methotrexate.  // Reactions Weekly;5/25/2013, Issue 1454, p10 

    An abstract of the article "A small cohort review of the long-term prognosis for Chinese older children and adolescents with acute lymphoblastic leukaemia treated on a paediatric protocol," by H. Xiong and colleagues is presented.

  • Asparaginase.  // Reactions Weekly;10/22/2011, Issue 1374, p10 

    The article describes the case of a 12- year-old boy who developed calcified catheter casts after removal of his central venous catheter (CVC) that was associated with asparaginase therapy for acute lymphoblastic leukaemia.

  • Asparaginase.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p45 

    The article presents a case study of an adult patient who developed an allergic reaction after receiving asparaginase for acute lymphoblastic leukaemia.

  • THE ADVERSE EFFECTS OF CHEMOTHERAPEUTIC AGENTS IN IRAQI PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA DURING THE INDUCTION PHASE. khudair Hassan, Mohammed; Jabir Ibrahim, Jaafar; Salem Abbas, Mohammed // International Journal of Advanced Biological Research;2013, Vol. 3 Issue 4, p584 

    Acute lymphoblastic leukemia (ALL) is a malignant transformation of a clone of cells from lymphoid progenitor cells. The aim of the present work was to study some of the adverse effects of the chemotherapeutic agents' methotrexate, vincristine, L-asparaginase, cytarabine and doxorubicin in Iraqi...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics